Genentech, Microbiotica to Develop Microbiome-Based IBD Treatments

Genentech, a member of the Roche Group, will partner with Microbiotica to discover, develop, and commercialize microbiome-based biomarkers and therapies for inflammatory bowel disease (IBD), through a collaboration that the Wellcome Trust Sanger Institute spinout said today could generate for it up to $534 million-plus.Under its multiyear strategic collaboration with Genentech, Microbiotica agreed to use its precision metagenomics microbiome platform to analyze patient samples from clinical tria